Elmar Nurmemmedov, PhD, MBA

Elmar has received his PhD degree from Lund University, Sweden, in molecular biophysics. During his postdoctoral training at Harvard Medical School, he contributed to drug discovery studies for sickle cell anemia. Subsequently during his postdoctoral training at Scripps Research Institute, Elmar successfully led the drug discovery effort for beta-catenin, a key regulator of colon cancer. Some of these studies led to preclinical drug development programs. Most recently, at Saint John’s Cancer Institute, Dr Nurmemmedov led the WNT research program with a focus on its therapeutic utility of novel therapeutics and combination therapies.